StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) company profile

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.43−0.05 (-3.38%)

Close on Nov 17, 2026Market cap $37.58MP/E –Yield –

About Elicio Therapeutics

Pharmaceutical Preparations, SIC 2834

Elicio Therapeutics is a clinical-stage biotechnology company that develops novel cancer immunotherapies, specifically targeting oncogenic drivers such as mutant Kirsten rat sarcoma viral oncogene homolog (mKRAS) in pancreatic, colorectal, and lung cancers. The company utilizes its proprietary Amphiphile platform, which leverages albumin hitchhiking to deliver therapeutic payloads directly to lymph nodes to generate robust, cancer-specific T cell responses. Its clinical pipeline is led by ELI-002, an off-the-shelf lymph-node-targeted peptide immunotherapy evaluated in Phase 1 and Phase 2 trials for mKRAS-driven solid tumors. Its preclinical programs include ELI-007 and ELI-008, targeting mutant BRAF and TP53 driver mutations, respectively, alongside potential platform applications for cellular therapies and auto-immune conditions.

The company engages in clinical and preclinical development through collaborative relationships with academic and medical institutions, including a worldwide patent licensing agreement with the Massachusetts Institute of Technology. The provided text details ongoing multicenter clinical evaluations and partnership opportunities across its immunotherapy pipeline, though it does not state specific facility numbers, operational countries, or the location of its corporate headquarters.

Summary of the business section of Elicio Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Elicio Therapeutics, Inc.
Headquarters
Boston, MA
Address
451 D Street, 5th Floor 02210
Phone
(857) 209-0050
Website
elicio.com
Employees
33, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, Tewksbury, MA

Stock & identifiers

Ticker
ELTX
Former tickers
ANGN until Jun 2, 2023
Exchange
Nasdaq
IPO date
Feb 5, 2021
Shares outstanding
26M, Aug 11, 2026
Public float
$81.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-95 reverse, Aug 14, 2023; 1-for-10 reverse, Jun 2, 2023
SEC CIK
1601485
CUSIP
28657F103
ISIN
US28657F1030
FIGI
BBG00444GM02
Share class FIGI
BBG00444GM11
LEI
254900EE2QKYD5SGI956
EIN
11-3430072

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert ConnellyCEO, President and Director120,570
Peter DeMuthChief Scientific Officer21,543
Christopher HaqqSee Remarks57,381
Preetam ShahSee Remarks24,000
Jay VenkatesanDirector180,534
Karen J. WilsonDirector18,718
Robert R. RuffoloDirector–
Yekaterina ChudnovskyDirector5,416,212
Allen NissensonDirector9,383
Carol Gail AsheDirector–
Julian AdamsDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Robert Connelly
President, Chief Executive Officer, and Director
$632.70K$906.96K$348.00K–$1.89M-7%
Preetam Shah
Chief Strategy and Financial Officer and Treasurer
$350.61K$796.14K$201.60K$29.33K$1.38M–
Christopher Haqq
Executive Vice President, Head of Research and Development and Chief Medical Officer
$528.10K$328.18K$221.90K–$1.08M+16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 5, 2021
Offer price
$16.00
Securities offered
5,000,000
Gross proceeds
$80.00M
Exchange
Nasdaq
First trading day
Feb 5, 2021
First-day close
$17.02+6.4%
Lock-up ends (est.)
Aug 4, 2021

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 33 employees, all of whom were full-time, 9 of whom have Ph.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 2, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 2, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 30, 2023Name changeName changed from Angion Biomedica Corp. to Elicio Therapeutics, Inc.
Feb 13, 2023MergerRegistration of securities for a merger or exchange offer (S-4)
Dec 22, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 5, 2021IPOInitial public offering priced (424B4 prospectus)
Feb 2, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?